We believe this coin's oversold condition presents an excellent entry point for long positions, aligning with our strategy to capitalise on a bullish reversal. We aim to maximise potential gains from this strategic repositioning by leveraging historical price patterns and technical analysis.
Let's dive in!
As you already know, based on the latest altcoin opportunity, the area of demand found here aligns nicely with a Fibonacci retracement level. This is also the price area that has served as support twice now despite significant bearish price action across the market.
The fact that this price point is holding up well provides us with a solid, well-justified entry point and a clear area to place stops to ensure we abide by our risk management protocols.
This isn't just a good return at 60% for spot holders; with the application of some leverage, it's a generous and well-justified opportunity with a clear technical conviction.
Injective's funding is 0.067%, indicating a relatively even balance between long and shorts. We would be cautious about entering long positions if an asset's funding rate was heavily positive, as seen for Injective in April.
However, the current balanced reading gives us the green light.

Open interest (the number of open leverage positions) has also decreased significantly compared to April, from 240.91 million to 72.38 million.
When open interest has significantly ramped up and is high compared to previous readings, and the funding rate is heavily positive, we would proceed with caution when building a long position. But neither of these conditions suggests a need for caution right now, giving us the green light from a market mechanics point of view.